9.08
0.22%
0.02
Cogent Biosciences Inc stock is traded at $9.08, with a volume of 1.83M.
It is up +0.22% in the last 24 hours and down -23.70% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
See More
Previous Close:
$9.06
Open:
$9.05
24h Volume:
1.83M
Relative Volume:
1.69
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-227.05M
P/E Ratio:
-4.1273
EPS:
-2.2
Net Cash Flow:
$-177.93M
1W Performance:
-12.69%
1M Performance:
-23.70%
6M Performance:
+15.82%
1Y Performance:
+20.58%
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
COGT | 9.08 | 1.00B | 0 | -227.05M | -177.93M | -2.20 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Feb-08-24 | Initiated | Citigroup | Buy |
Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
Dec-08-23 | Initiated | JP Morgan | Overweight |
Apr-28-23 | Initiated | Robert W. Baird | Outperform |
Mar-27-23 | Resumed | H.C. Wainwright | Buy |
Dec-14-22 | Initiated | Needham | Buy |
Jun-28-22 | Initiated | Guggenheim | Buy |
Oct-11-21 | Initiated | H.C. Wainwright | Buy |
Jun-09-21 | Resumed | Jefferies | Buy |
Dec-23-20 | Initiated | Piper Sandler | Overweight |
Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World
FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - MarketBeat
Trend Tracker for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat
Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World
Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat
Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat
FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat
COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat
Cogent Biosciences Inc (COGT) Quarterly 10-Q Report - Quartz
Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing - TipRanks
Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire
Cogent Biosciences Reports Strong Pipeline Progress, $346M Cash Position Despite Q3 Losses | COGT Stock News - StockTitan
Creative Planning Buys 3,272 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences’ (COGT) Buy Rating Reaffirmed at HC Wainwright - Defense World
FMR LLC Acquires Additional Shares in Cogent Biosciences Inc - GuruFocus.com
(COGT) Trading Advice - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3%Here's What Happened - MarketBeat
Cogent Biosciences Announces Bezuclastinib Presentations at - GlobeNewswire
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting - The Manila Times
Cogent Biosciences to Present Key Bezuclastinib Trial Data at ASH 2024 Meeting | COGT Stock News - StockTitan
Cogent Biosciences' (COGT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.67 Average PT from Brokerages - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(COGT) Investment Analysis - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Purchases 44,287 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences' (COGT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Cogent Biosciences expands pipeline with KRAS inhibitor - Investing.com
Cogent Biosciences expands pipeline with KRAS inhibitor By Investing.com - Investing.com UK
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics - StockTitan
Cogent Biosciences Announces Pipeline Expansion into KRAS - GlobeNewswire
COGT Stock Hits 52-Week High at $12.2 Amid Market Optimism - Investing.com India
Cogent Biosciences (NASDAQ:COGT) Sets New 52-Week HighHere's What Happened - MarketBeat
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
The Manufacturers Life Insurance Company Has $301,000 Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Market Momentum Report: Cogent Biosciences Inc (COGT)’s Negative Close at 11.35 - The Dwinnex
Cogent Biosciences (NASDAQ:COGT) Shares Down 2.4%What's Next? - MarketBeat
(COGT) Technical Data - Stock Traders Daily
Stocks of Cogent Biosciences Inc (COGT) are poised to climb above their peers - SETE News
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.6%Here's What Happened - MarketBeat
Did Cogent Biosciences Inc (COGT) perform well in the last session? - US Post News
Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target - Insider Monkey
Get in on Cogent Biosciences Inc’s (COGT) buy-in window today! - SETE News
Metric Deep Dive: Understanding Cogent Biosciences Inc (COGT) Through its Ratios - The Dwinnex
Dimensional Fund Advisors LP Has $7.84 Million Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):